Boron Olefination Reagent for Statin Intermediate Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional synthetic methods for statins, particularly those with E geometric isomerism, face challenges such as low selectivity towards the trans (E) isomer, leading to cis (Z) isomer impurities and the use of high-molecular-weight reagents like phosphorous or sulfur compounds, which increase costs and complexity.
Innovation Solution
A process for preparing a key intermediate for statins using a compound of formula (I) that involves a reaction between compounds of formulas (II) and (III) in the presence of a Lewis acid and a base, avoiding phosphorus or sulfur atoms, resulting in a highly regioselective product with a trans (E) double bond configuration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional olefination reactions (Wittig, Horner-Emmons, or Julia reactions) are used to synthesize statins with E geometric isomerism, then the reaction can proceed to form the trans (E) isomer, but the reaction is not highly selective and also forms cis (Z) isomer impurities that are difficult to remove
Solution Approach 1:
The patent changes the chemical parameters of the reaction by replacing traditional phosphorous or sulfur-based reagents with a boron-containing compound (formula I) as the olefination reagent. This parameter change in the reagent structure leads to high regioselectivity for the trans (E) isomer, eliminating the formation of cis (Z) isomer impurities that plague traditional methods.
2Ease of manufacture
If phosphorous, phosphorane or sulphone reagents are used in olefination reactions, then the reaction can proceed, but the side products (phosphin oxides or sulphur compounds) are difficult to remove from reaction mixtures, thus increasing the whole cost of synthesis
Solution Approach 1:
The patent extracts or removes the problematic phosphorous and sulfur elements from the reaction system by using a boron-containing compound instead. This substitution eliminates the formation of difficult-to-remove phosphin oxides and sulphur compounds, thereby simplifying purification and reducing synthesis costs.
Solution Approach 2:
The boron-containing reagent (formula I) serves as a disposable reagent that converts into easily removable byproducts. Unlike persistent phosphorous and sulfur compounds, the boron-based reagent system allows for simpler waste management and purification, reducing overall process costs.
3Ease of manufacture
If high-molecular-weight reagents like triphenylphosphine ylides are used, then the reaction can proceed, but the molar weight of reagents is very high compared to the side chain, thus the productivity of the process is quite low since it is necessary to handle large amounts of reagents to obtain relatively low amounts of products
Solution Approach 1:
The patent employs a boron-containing compound (formula I) as a lightweight, disposable reagent that is stoichiometrically efficient. The reagent has a much lower molecular weight compared to traditional triphenylphosphine ylides, allowing for higher productivity with smaller reagent quantities while maintaining effective olefination reaction capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enhances productivity by eliminating impurities and reducing waste, achieving higher molar yields and providing a more economical synthesis of statins like Rosuvastatin, Pitavastatin, and Fluvastatin with improved selectivity and reduced side product management.
Implementation Method 1
A process for the preparation of a key intermediate for the synthesis of statins and salts thereof as outlined in the annexed claims... in the presence of a Lewis acid and a base
Data Source
AI summary
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.